0001367644-23-000160.txt : 20230816 0001367644-23-000160.hdr.sgml : 20230816 20230816164732 ACCESSION NUMBER: 0001367644-23-000160 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230811 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230816 DATE AS OF CHANGE: 20230816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 231178763 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 8-K 1 ebs-20230811.htm 8-K ebs-20230811
0001367644false00013676442023-08-112023-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 11, 2023
 
EMERGENT BIOSOLUTIONS INC.
(Exact name of registrant as specified in its charter)
 
Delaware001-3313714-1902018
(State or other jurisdiction(Commission File Number)(IRS Employer
of incorporation)Identification No.)
 400 Professional Drive, Suite 400,
Gaithersburg, Maryland 20879
(Address of principal executive offices, including zip code)
 
(240) 631-3200
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, Par Value $0.001 per shareEBSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company     ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 16, 2023, Emergent BioSolutions Inc. (the “Company”), announced that Jerome Hauer, Ph.D., a director of the Company, had passed away on Friday August 11, 2023. Dr. Hauer served as a director since January 2015 and previously served on the company’s Board of Directors from May 2004 to October 2011.
Item 7.01. Regulation FD Disclosure.
On August 16, 2023, the Company issued a statement regarding Dr. Hauer’s passing, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01.  Financial Statements and Exhibits
(d) Exhibits.
Exhibit No.Description
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EMERGENT BIOSOLUTIONS INC.
   
Dated: August 16, 2023By:/s/ RICHARD S. LINDAHL
Name: Richard S. Lindahl
Title: Executive Vice President, Chief Financial
              Officer and Treasurer



 EX-99.1 2 a08162023-drhauer.htm EX-99.1 Document
image.jpg



Emergent’s Statement Regarding the Passing of a Director of the Board

GAITHERSBURG, Md., August 16, 2023 – Emergent (NYSE: EBS) shares with deep sadness that Dr. Jerome Hauer, long-time member of Emergent’s Board of Directors and public health pioneer, passed away peacefully at his home, on August 11, 2023, after a hard-fought battle with cancer. We express our deepest condolences to Dr. Hauer’s wife, Traci, his extended family, and friends.

Throughout his career, Dr. Hauer held several important positions in government agencies and private organizations, as well as various academic and consulting roles related to emergency preparedness, biosecurity, and public health. Dr. Hauer is best known for his leadership and contributions in preparing for and responding to various emergencies and disasters, including natural disasters, disease outbreaks and acts of terrorism. As New York City's first director of the Office of Emergency Management during the September 11, 2001, attacks on the World Trade Center, his leadership and coordination efforts were applauded for being instrumental in managing the response to the attacks and their aftermath.

In addition to his unmatched work in the field of emergency management, we honor his service to our nation as captain in the United States Army Reserves Medical Services Corps.

Dr. Hauer’s commitment, passion, and dedication to safeguard the public were shared values of Emergent’s mission to protect and enhance life. We will carry Dr. Hauer’s virtues of servant leadership, guardianship of public health and integrity in our work to continue his legacy.

He will forever be in our hearts with great admiration and will be missed dearly.

Media Contact:
Matt Hartwig
Director, Media Relations
240-760-0551
hartwigm@ebsi.com

Investor Contact:
Richard Lindahl
EVP and Chief Financial Officer
240-631-3360
lindahlr@ebsi.com
1
 EX-101.SCH 3 ebs-20230811.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ebs-20230811_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 ebs-20230811_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image.jpg begin 644 image.jpg MB5!.1PT*&@H -24A$4@ 3( C" 8 7.X9/ 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page Cover Page
Aug. 11, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 11, 2023
Entity Registrant Name EMERGENT BIOSOLUTIONS INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-33137
Entity Tax Identification Number 14-1902018
Entity Address, Address Line One 400 Professional Drive
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20879
City Area Code 240
Local Phone Number 631-3200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Title of 12(b) Security Common Stock, Par Value $0.001 per share
Trading Symbol EBS
Security Exchange Name NYSE
Entity Central Index Key 0001367644
Amendment Flag false

XML 8 ebs-20230811_htm.xml IDEA: XBRL DOCUMENT 0001367644 2023-08-11 2023-08-11 0001367644 false 8-K 2023-08-11 2023-08-11 EMERGENT BIOSOLUTIONS INC. DE 001-33137 14-1902018 400 Professional Drive Suite 400 Gaithersburg MD 20879 240 631-3200 false false false false Common Stock, Par Value $0.001 per share EBS NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Cover Page Sheet http://emergentbiosolutions.com/role/CoverPageCoverPage Cover Page Cover Page Cover 1 false false All Reports Book All Reports ebs-20230811.htm a08162023-drhauer.htm ebs-20230811.xsd ebs-20230811_lab.xml ebs-20230811_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ebs-20230811.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "ebs-20230811.htm" ] }, "labelLink": { "local": [ "ebs-20230811_lab.xml" ] }, "presentationLink": { "local": [ "ebs-20230811_pre.xml" ] }, "schema": { "local": [ "ebs-20230811.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ebs", "nsuri": "http://emergentbiosolutions.com/20230811", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ebs-20230811.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page Cover Page", "menuCat": "Cover", "order": "1", "role": "http://emergentbiosolutions.com/role/CoverPageCoverPage", "shortName": "Cover Page Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ebs-20230811.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://emergentbiosolutions.com/role/CoverPageCoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001367644-23-000160-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001367644-23-000160-xbrl.zip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end